YLYang Liu

Yang Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yang Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characterization of the Chemical Constituents in Shenyanshu Tablets by Ultra‐High‐Performance Liquid Chromatography Quadrupole Time‐of‐Flight Mass Spectrometry

    by Xing Wang, Jiao Guan, Chunfu Zhang, Yanwu Guan, Lihe Wang, Yan Yang, Shuangyu Li, Yang Liu, Lele Li, Yue Cui, et al.

    Shenyanshu tablets (SYST), a widely prescribed traditional Chinese patent medicine, which is clinically applied to treat chronic glomerulonephritis in China and other Asian countries. However, there is still no detailed report existing on its chemical composition at present, which hinders further investigation into its pharmacological activities and mechanism of action. To solve this difficult problem, an ultra‐high‐performance liquid chromatography quadrupole time‐of‐flight mass spectrometry method was established to separate and identify the chemical constituents of SYST. A total of 130 compounds were identified or characterized, among which 19 compounds were clearly confirmed by comparing their retention time and mass spectrometry data with those of reference standards. Based on the mass spectrometry data and relevant literature, the remaining compounds were preliminarily characterized. Results revealed that flavonoids, triterpenoid glycosides, organic acids, and alkaloids were the primary chemical components of SYST. The established analytical method has been proven to effectively characterize the chemical constituents of SYST and also provides important reference for clarifying the pharmacodynamic material basis and mechanism of action of SYST.

  • Identification of the Absorbed Constituents and Metabolites of Shenyanshu Tablets in Rat Plasma by Ultrahigh‐Performance Liquid Chromatography Coupled With Quadrupole Time‐of‐Flight Mass Spectrometry

    by Xing Wang, Shengyu Ge, ChunFu Zhang, Lihe Wang, Yan Yang, Shuangyu Li, Yang Liu, Lele Li, Renbo An, Jiao Guan, et al.

    Shenyanshu Tablets (SYST) is a traditional Chinese patent medicine composed of 10 kinds of Chinese herbal medicines, which has the functions of tonifying the kidney and strengthening the spleen, promoting diuresis and reducing swelling. It is well known that SYST can be used to treat chronic nephritis. However, due to the complexity of the formula, the pharmacological active components in SYST that can be absorbed into plasma have not been fully studied. In this study, an ultrahigh‐performance liquid chromatography coupled with quadrupole time‐of‐flight mass spectrometry (UHPLC‐Q‐TOF‐MS) method was first developed for separating and identifying the absorbed components and metabolites of SYST in rat plasma. A total of 33 compounds were identified or preliminarily characterized, including 18 prototype components and 15 metabolites. The results demonstrated that alkaloids, fatty acids, organic acids, and triterpenoid glycosides were the main prototype components, and triterpenoid glycoside–related metabolites, fatty acid–related metabolites, and flavonoid‐related metabolites were the major metabolites. These findings clarify the material basis of SYST in the treatment of chronic nephritis and provide references for further research and development of SYST.

  • Integrated UHPLC‐Q‐TOF‐MS Technology and Network Pharmacology Exploring the Pharmacodynamic Material Basis and Mechanism of Zhi‐Zi‐Hou‐Po Granule for Treatment of Depression–Anxiety Comorbidity

    by Yang Liu, Jiao Guan, Yan Yang, Xing Wang, Shuangyu Li, Shengyu Ge, Bo Feng, Lele Li, Lili Jin, Heyun Zhu

    Zhi‐Zi‐Hou‐Po Decoction (ZZHPD) is a classic traditional Chinese medicine (TCM) formula for treating depression and anxiety. Considering the disadvantages of decoction, our research group prepared ZZHPD into Zhi‐Zi‐Hou‐Po Granule (ZZHPG). However, the chemical composition and mechanism of ZZHPG for the treatment of depression–anxiety comorbidity remain unclear. In this study, the UHPLC‐Q‐TOF‐MS technology was applied to investigate the chemical constituents in ZZHPG, and network pharmacology was used to reveal the mechanism of ZZHPG. A total of 92 compounds were identified in ZZHPG. The network pharmacological analysis showed that 92 compounds regulated 132 pathways through 90 targets, among which 17 compounds maybe the material basis of ZZHPG for the treatment of depression–anxiety comorbidity, and osthole, obovatol, and naringenin may be the main pharmacodynamic components. Further research indicated that the mechanism of ZZHPG in treating depression–anxiety comorbidity may be related to the inhibition of nervous system disorders, activation of GABA receptors, anti‐inflammation, and reduction of oxidative stress. The molecular docking results showed that osthole, obovatol, and naringenin exhibited strong binding affinity with the core targets AKT1, ALB, TNF, EGFR, ESR1, and GSK3B. This research laid foundation for clinical application of ZZHPG and provided new ideas for the study of other TCM prescriptions.

  • Pharmacodynamic Material Basis and Pharmacological Mechanism of Huangqi Guizhi Wuwu Granules in Diabetic Peripheral Neuropathy

    by Yang Liu, Lele Li, Yan Yang, Xing Wang, Shengyu Ge, Lili Jin, Bo Feng, Jiao Guan, Heyun Zhu

    Huangqi Guizhi Wuwu Decoction (HGWD) is a traditional Chinese medicine (TCM) formula used to treat diabetic peripheral neuropathy (DPN) in China. Considering that the decoction was not easy to carry and use, we have prepared HGWD into Huangqi Guizhi Wuwu Granules (HGWG). However, the active components of HGWG that can be absorbed into plasma and its mechanism of action for DPN treatment remain unclear. In the present study, UHPLC‐Q‐TOF‐MS and network pharmacology methods were applied to explore the potential pharmacodynamic material basis and pharmacological mechanism of HGWG for the treatment of DPN. A total of 31 absorbed components were detected in rat plasma, including 20 prototype compounds and 11 metabolites. Flavonoid‐related metabolites and gingerol‐related metabolites were major metabolites. The network pharmacological analysis showed that 31 absorbed constituents regulated 122 pathways through 177 targets; among them, baicalein, paeoniflorin C, and 6‐gingerol were the main pharmacodynamic components of HGWG for DPN. It can be concluded that monoterpenoid glycosides, flavonoids, organic acids, gingerols, flavonoid‐related metabolites, and gingerol‐related metabolites were the main pharmacodynamic material basis of HGWG for DPN, and the mechanism of HGWG for DPN may be related to reducing oxidative stress and inhibiting neuroinflammation by stimulating the phosphorylation of p38 MAPK.